AbbVie has launched as an independent biopharmaceutical company, as Abbott completed the separation from the research arm of its pharmaceutical business.
AbbVie launches with an estimated $18 billion in annual revenues, a team of experienced senior leaders, and a broad portfolio that includes Humira, AndroGel, Lupron, Synagis, Creon, Synthroid, Kaletra, Norvir and Zemplar. The company will also keep the Abbott Contract Manufacturing business.
"Today AbbVie launches with an outstanding portfolio, a solid pipeline and enthusiastic people who will serve patients and deliver growth," said Richard A. Gonzalez, chairman of the board and chief executive officer, AbbVie. "With those assets and a relentless focus on innovation we intend to create significant value for our shareholders."
"We wish our colleagues at AbbVie continued success as they become part of a new, independent company that is already making a significant difference, focusing on highly specialized, market-leading therapies for some of the world's most difficult-to-treat diseases," said Miles D. White, chairman and chief executive officer, Abbott.